Ectopic ACTH Syndrome: Bridging Severe Hypercortisolism While the Tumor Is Still Being Found
A single patient whose hypercortisolism is severe and fast-moving enough that treatment cannot wait for the slow process of finding its actual source.
Douglas M., a 55-year-old former commercial fisherman, was admitted four days ago with confusion, new-onset diabetes with a glucose of 480, and a potassium of 2.6 despite aggressive repletion — severe enough that cardiology was consulted before endocrinology was. His daughter, who drove three hours to be at the bedside, keeps telling the team he "was fine six weeks ago," a timeline she repeats almost like a question, as if saying it enough times might make the speed of his decline make more sense. His ACTH came back at 312 pg/mL, markedly higher than the range typical Cushing's disease usually produces, and his cortisol excess has developed over roughly six weeks, far faster than the years-long course a pituitary or adrenal source usually takes. Both of those facts, plus his profound hypokalemia — a classic finding in ectopic ACTH syndrome specifically, since cortisol at very high concentrations overwhelms the enzyme that normally keeps it from acting on the kidney's mineralocorticoid receptor, making cortisol itself behave like aldosterone — point toward an ectopic ACTH-producing tumor rather than a pituitary corticotroph adenoma, most often a small cell lung cancer or bronchial carcinoid in patients his age with his smoking history.
Finding that tumor is not fast. Localization typically requires cross-sectional imaging of the chest, abdomen, and pelvis, often followed by somatostatin-receptor imaging for a small neuroendocrine primary that a standard CT can miss entirely, and sometimes inferior petrosal sinus sampling first, specifically to rule out an unusually ACTH-avid pituitary source before assuming ectopic disease. That workup can take days to weeks. His metabolic derangement — the potassium, the glucose, the confusion — cannot wait that long, which is exactly why medical cortisol-synthesis blockade exists as a bridge: control the hormone while the source is still being found, not after.
ICU bedside, day 4, localization imaging pending
His potassium is 2.6 despite repletion, his glucose is 480, and he's confused — this is not a picture that can wait for imaging to find the tumor before we control the hormone driving it. I'd start metyrapone and ketoconazole together now — Corcuff's series showed that pairing bringing severe neoplastic hypercortisolism down within days — given how much combination therapy speeds cortisol control in exactly this kind of acute, severe presentation.
I agree we can't wait for localization, but combining two potent steroidogenesis inhibitors in a patient this unstable, without knowing his individual sensitivity, carries a real risk of its own — precipitating acute adrenal insufficiency on top of everything else already going on. I'd start with metyrapone alone, titrate against serial cortisol checks, and add ketoconazole only if a single agent isn't controlling him fast enough.
So tell me what we'd do at hour six if his cortisol has fallen through the floor and we can't say which of the two drugs did it. Starting them together buys speed and gives up the one thing that makes an over-suppression recoverable, which is knowing what to stop.
There's a real question underneath both of your plans — can we actually count on oral absorption right now, given how his mental status has been fluctuating? IV etomidate is an established acute cortisol-lowering bridge specifically for critically ill patients whose oral intake isn't reliable. I don't think that's a fringe option here. I'd start a low-dose etomidate infusion with continuous monitoring while his mental status is this unpredictable, and transition to an oral agent once he can reliably take and absorb one.
Agreed: start a low-dose IV etomidate infusion with continuous monitoring while his mental status remains unpredictable, transitioning to oral metyrapone once intake is reliable, with localization imaging continuing in parallel rather than delayed for the medical bridge.
Not agreed: how quickly to escalate to combination oral therapy once he transitions off etomidate. The endocrinologist would move to combination therapy promptly given his severity; the pharmacologist wants a genuine single-agent titration trial first, even post-transition, before adding a second steroidogenesis inhibitor.